NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
The GM2 gangliosidoses are caused by incomplete catabolism of GM2 ganglioside in the lysosome, leading to progressive storage and a neurodegenerative clinical course. An inflammatory response (microglial activation, macrophage infiltration, oxidative damage) has been found to be a consequence of GM2...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2004
|
| _version_ | 1797079179666128896 |
|---|---|
| author | Jeyakumar, M Smith, D Williams, I Borja, M Neville, D Butters, T Dwek, R Platt, F |
| author_facet | Jeyakumar, M Smith, D Williams, I Borja, M Neville, D Butters, T Dwek, R Platt, F |
| author_sort | Jeyakumar, M |
| collection | OXFORD |
| description | The GM2 gangliosidoses are caused by incomplete catabolism of GM2 ganglioside in the lysosome, leading to progressive storage and a neurodegenerative clinical course. An inflammatory response (microglial activation, macrophage infiltration, oxidative damage) has been found to be a consequence of GM2 storage in the brain, although it remains unclear whether this contributes to pathogenesis or disease progression. In this study, we treated Sandhoff disease mice with nonsteroidal antiinflammatory drugs (indomethacin, aspirin, and ibuprofen) and antioxidants (L-ascorbic acid and alpha-tocopherol acetate). The treated mice lived significantly longer than untreated littermates (12-23%, p <0.0001) and showed a slower rate of disease progression (p <0.001). When aspirin treatment was combined with substrate reduction therapy, synergy resulted (11%, p <0.05) with a maximum improvement of 73% in survival (p <0.00001). This study demonstrates that inflammation contributes to disease progression and identifies antiinflammatory and antioxidant therapies as a potential adjunctive approach to slow the clinical course of this and related disorders. |
| first_indexed | 2024-03-07T00:42:03Z |
| format | Journal article |
| id | oxford-uuid:835ffc65-05f1-4461-a6bf-f4d02085b92b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:42:03Z |
| publishDate | 2004 |
| record_format | dspace |
| spelling | oxford-uuid:835ffc65-05f1-4461-a6bf-f4d02085b92b2022-03-26T21:43:48ZNSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:835ffc65-05f1-4461-a6bf-f4d02085b92bEnglishSymplectic Elements at Oxford2004Jeyakumar, MSmith, DWilliams, IBorja, MNeville, DButters, TDwek, RPlatt, FThe GM2 gangliosidoses are caused by incomplete catabolism of GM2 ganglioside in the lysosome, leading to progressive storage and a neurodegenerative clinical course. An inflammatory response (microglial activation, macrophage infiltration, oxidative damage) has been found to be a consequence of GM2 storage in the brain, although it remains unclear whether this contributes to pathogenesis or disease progression. In this study, we treated Sandhoff disease mice with nonsteroidal antiinflammatory drugs (indomethacin, aspirin, and ibuprofen) and antioxidants (L-ascorbic acid and alpha-tocopherol acetate). The treated mice lived significantly longer than untreated littermates (12-23%, p <0.0001) and showed a slower rate of disease progression (p <0.001). When aspirin treatment was combined with substrate reduction therapy, synergy resulted (11%, p <0.05) with a maximum improvement of 73% in survival (p <0.00001). This study demonstrates that inflammation contributes to disease progression and identifies antiinflammatory and antioxidant therapies as a potential adjunctive approach to slow the clinical course of this and related disorders. |
| spellingShingle | Jeyakumar, M Smith, D Williams, I Borja, M Neville, D Butters, T Dwek, R Platt, F NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. |
| title | NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. |
| title_full | NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. |
| title_fullStr | NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. |
| title_full_unstemmed | NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. |
| title_short | NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. |
| title_sort | nsaids increase survival in the sandhoff disease mouse synergy with n butyldeoxynojirimycin |
| work_keys_str_mv | AT jeyakumarm nsaidsincreasesurvivalinthesandhoffdiseasemousesynergywithnbutyldeoxynojirimycin AT smithd nsaidsincreasesurvivalinthesandhoffdiseasemousesynergywithnbutyldeoxynojirimycin AT williamsi nsaidsincreasesurvivalinthesandhoffdiseasemousesynergywithnbutyldeoxynojirimycin AT borjam nsaidsincreasesurvivalinthesandhoffdiseasemousesynergywithnbutyldeoxynojirimycin AT nevilled nsaidsincreasesurvivalinthesandhoffdiseasemousesynergywithnbutyldeoxynojirimycin AT butterst nsaidsincreasesurvivalinthesandhoffdiseasemousesynergywithnbutyldeoxynojirimycin AT dwekr nsaidsincreasesurvivalinthesandhoffdiseasemousesynergywithnbutyldeoxynojirimycin AT plattf nsaidsincreasesurvivalinthesandhoffdiseasemousesynergywithnbutyldeoxynojirimycin |